Related Experiment Video
Updated: Aug 13, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
A mini-review of c-Met as a potential therapeutic target in melanoma
Doa'a G F Al-U'datt1, Belal A A Al-Husein2, Ghazi Raji Qasaimeh3
1Department of Pharmacology and Physiology, Faculty of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Abstract:
Melanoma is the third highest rated cancer in prevalence. Surgery, radiotherapy and targeted/biological therapies in addition to chemotherapy are available options for management of this cancer. Met is an appealing target for management of this type of cancer, since it targets many cancer vital processors, such as angiogenesis, cell growth, scattering and differentiation. In this review, we provide an overview about pathway abnormalities associated with melanoma. We also provide a summary about the events involved in Met signaling and related signaling molecules. We also show the evidence of the importance of Met signaling pathway as a target in cancer management. We also summarize clinical evidence about the use of Met signaling in management of cancer and summarize available trials related to targeting Met in other cancers.
Insights
Met signaling is crucial for melanoma progression, impacting angiogenesis and cell growth. Targeting this pathway offers a promising therapeutic strategy for melanoma and other cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Melanoma is a significant cancer with available treatments like surgery, chemotherapy, and targeted therapies.
- The Met signaling pathway is implicated in vital cancer processes including angiogenesis, cell growth, scattering, and differentiation.
Purpose of the Study:
- To review pathway abnormalities in melanoma.
- To summarize Met signaling events and related molecules.
- To highlight the importance of Met signaling as a cancer management target.
Main Methods:
- Literature review of Met signaling in melanoma.
- Analysis of Met pathway abnormalities and associated molecules.
- Summary of clinical evidence and trials for Met-targeted therapies.
Main Results:
- Met signaling pathway abnormalities are associated with melanoma.
- Met signaling plays a key role in cancer progression.
- Evidence supports Met signaling as a viable therapeutic target.
Conclusions:
- Met signaling pathway is a critical target for melanoma management.
- Targeting Met signaling shows potential in clinical applications for various cancers.
- Further research and clinical trials are warranted for Met-targeted therapies.
Related Concept Videos
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...